Grants and Sponsored Research:

• September 2018–August 2020
  Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction
  Role: Principal Investigator
  
• March 2013–March 2018
  First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
  National Eye Institute
  Role: Principal Investigator
  $240,000
• August 2013–June 2017
  A Randomized, Placebo-controlled, Parallel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease
  Role: Principal Investigator
  
• August 2012–September 2016
  A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal injection for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye
  Role: Principal Investigator
  
• May 2013–July 2016
  A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the With Amnestic Mild Alzheimer's Disease (Prodromal AD) Cognitive Impairment Due to Efficacy and Safety of MK-8931 (SCH 900931)
  Role: Principal Investigator
  
• March 2012–May 2016
  A Randomized Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan- uveitis currently controlled with systemic treatment
  Role: Principal Investigator
  $9,000
• January 2011–January 2016
  Multi-center Uveitis Steroid Treatment (MUST) Trial
  John Hopkins University
  Role: Co-Principal Investigator
  $278,419
• July 2009–October 2013
  Studies of the Ocular Complications of AIDS (SOCA)
  National Eye Institute Grant
  Role: Co-Principal Investigator
  $115,525
• July 2009–March 2013
  Sub Investigator A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment–Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an as Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR)
  Role: Co-Principal Investigator
  $395,000
• July 2009–November 2012
  A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety Of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (RISE)
  Role: Co-Principal Investigator
  $544,120
• January 2023
  A MULTI-CENTER, NON-RANDOMIZED, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7497372 FOLLOWING INTRAVITREAL ADMINISTRATION IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA
  Role: Principal Investigator
  

Patents:

• ADVANCED PROTECTIVE CLEAR DOME SHIELD FOR OPTICAL INSTRUMENTS (2022)
• Quantitative image analysis applied to the grading of vitreous haze (2016)